Seer (SEER)
NASDAQ:SEER
Want to see SEER full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced clear short-term commercial and margin headwinds (33% YoY revenue decline, compressed gross margin to 35%, negative free cash flow) with multiple strategic positives: rapidly expanding scientific validation (publications doubled YoY), major population-scale biobank partnerships (PRECISE-SG100K and others), continued product and analytics innovation (SP200, Proteograph One Assay, next-gen detector, Raviant DIA), meaningful operating expense reductions (~20% YoY), improved net loss, strong cash position ($219.5M) and active share repurchases. Management reaffirmed full-year guidance and is taking defensive IP/legal actions against imitators while adding seasoned commercial leadership to drive commercialization. Overall, the call signals durable long-term opportunity and disciplined financial management but acknowledges near-term revenue and margin pressures.Company Guidance
Rapid Growth in Peer-Reviewed Validation
Publications validating the Proteograph product suite reached 84 (vs. 42 as of March 2025 and 3 in 2022), effectively doubling year-over-year (~+100% YoY) and strengthening scientific credibility.
Major Population-Scale Biobank Collaborations
Announced PRECISE-SG100K collaboration with PRECISE and Thermo Fisher to generate proteomics for 10,000 participants with potential to expand to 100,000, and ongoing population-scale work with Korea University and NIH-funded multi-omic study — catalytic for long-term demand.
Notable Clinical/Translational Impact Example
Customer PrognomIQ used the Proteograph in ProVue Lung: in the first 78 high-risk adults the test detected 8 lung cancers (overall sensitivity 89% at 64% specificity; stage 1 sensitivity 83%) — demonstrates meaningful applicability for early cancer detection.
Strengthened Commercial Leadership
Appointed Tony Bazarko as Chief Commercial Officer to scale go-to-market efforts and accelerate biobank and biopharma adoption at a pivotal moment for the business.
Defended and Expanded Intellectual Property
PTAB upheld 23 of 29 claims in a nanoparticle enrichment patent; company reports >250 patents/applications with 84 issued patents and initiated a patent infringement suit against a competitor, underscoring IP protection efforts.
Product and Analytics Innovation
Introduced SP200 and Proteograph One Assay to enable large-scale studies, progressing next-generation detector (data showcase expected later this year), launched POS update with chatbot/notebook interfaces, and filed Raviant DIA preprint — continued R&D breadth.
Operating Expense Discipline
Total operating expenses decreased from $22.8M in Q1 2025 to $18.2M in Q1 2026, a reduction of $4.6M (~20% YoY), reflecting deliberate cost control while investing in priority initiatives.
Improved Loss Profile and Strong Cash Position
Net loss improved to $16.8M in Q1 2026 from $19.9M in Q1 2025 (improvement of $3.1M, ~15.6% reduction). Company ended the quarter with $219.5M in cash, cash equivalents and investments and believes it has sufficient capital to reach cash-flow breakeven.
Share Repurchase Activity
Repurchased ~1.5M Class A shares in Q1 at $1.78 average; total repurchases to date ~13.2M shares at VWAP $1.86 using ~$24.5M of the prior $25M program, reducing total common shares outstanding by ~15%.
Reaffirmed Full-Year Guidance
Reaffirmed 2026 revenue guidance of $16M–$18M (midpoint ~$17M), representing ~3% growth at the midpoint vs. full year 2025, signaling management confidence despite near-term headwinds.
SEER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SEER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.77 | $1.75 | -1.13% |
Feb 26, 2026 | $2.08 | $1.72 | -17.31% |
Nov 06, 2025 | $2.16 | $2.09 | -3.24% |
Aug 06, 2025 | $2.06 | $2.01 | -2.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Seer (SEER) report earnings?
Seer (SEER) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Seer (SEER) earnings time?
Seer (SEER) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SEER EPS forecast?
SEER EPS forecast for the fiscal quarter 2026 (Q2) is -0.22.